Ausgabe 6/2013
Inhalt (27 Artikel)
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
Chi Hang Wong, Herbert H. Loong, Connie W. C. Hui, Cecilia P. Y. Lau, Edwin P. Hui, Brigette B. Y. Ma, Anthony T. C. Chan
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
Maria Ait-Tihyaty, Zakaria Rachid, Anne-Laure Larroque-Lombard, Bertrand J. Jean-Claude
Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme
Elita F. da Silveira, Janaine M. Chassot, Fernanda C. Teixeira, Juliana H. Azambuja, Gabriela Debom, Fátima T. Beira, Francisco A. B. Del Pino, Adriana Lourenço, Ana P. Horn, Letícia Cruz, Roselia M. Spanevello, Elizandra Braganhol
OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model
Ilya Tsimafeyeu, Elina Zaveleva, Evgenia Stepanova, Walter Low
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)
Godefridus J. Peters, Kees Smid, Leonardo Vecchi, Ietje Kathmann, Dzjemma Sarkisjan, Richard J. Honeywell, Nienke Losekoot, Osnat Ohne, Aric Orbach, Eran Blaugrund, Lak Shin Jeong, Young Bok Lee, Chang-Ho Ahn, Deog Joong Kim
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation
Ji-Young Song, Choung-Soo Kim, Je-Hwan Lee, Se Jin Jang, Sang-wook Lee, Jung Jin Hwang, Chulsoo Lim, Gilnam Lee, Jeongbeob Seo, Suk Young Cho, Jene Choi
Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition
Cheree Fitzgibbon, Saleh Ihmaid, Jasim Al-Rawi, Terri Meehan-Andrews, Christopher Bradley
Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats
Romit Chakrabarty, Hue Tran, Iohann Boulay, Tanya Moran, Audrey Parenteau, Robert Tavcar, Maude Bigras, Allison Hagerman, Sarah Serl, Brad Thompson, Matt Coffey
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
Normand Blais, D. Ross Camidge, Derek J. Jonker, Denis Soulières, Scott A. Laurie, Sami G. Diab, Ana Ruiz-Garcia, Aron Thall, Ke Zhang, Richard C. Chao, Laura Q. Chow
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Philipp Harter, Jalid Sehouli, Rainer Kimmig, Jörn Rau, Felix Hilpert, Christian Kurzeder, Gabriele Elser, Andreas du Bois
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
Prasanth Ganesan, Sarina Piha-Paul, Aung Naing, Gerald Falchook, Jennifer Wheler, Filip Janku, Ralph Zinner, Shell Laday, Merrill Kies, Apostolia M. Tsimberidou
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas
Seok Jin Kim, Hye Jin Kang, Jin Seok Kim, Hyeon-Seok Eom, Jooryung Huh, Young Hyeh Ko, Jongtae Lee, Dong-Seok Yim, Soo-Youn Lee, Weon Seo Park, Woo Ick Yang, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S. F. Dent, K. A. Gelmon, K. N. Chi, D. J. Jonker, N. Wainman, C. A. Capier, E. X. Chen, J. F. Lyons, L. Seymour
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
A. Hollebecque, E. Deutsch, C. Massard, C. Gomez-Roca, R. Bahleda, V. Ribrag, C. Bourgier, V. Lazar, L. Lacroix, A. Gazzah, A. Varga, T. de Baere, F. Beier, S. Kroesser, K. Trang, F. T. Zenke, M. Klevesath, Jean-Charles Soria
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
William R. Schelman, Anne M. Traynor, Kyle D. Holen, Jill M. Kolesar, Steven Attia, Tien Hoang, Jens Eickhoff, Zhisheng Jiang, Dona Alberti, Rebecca Marnocha, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Igor Espinoza-Delgado, John J. Wright, George Wilding, Howard H. Bailey
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
K.-W. Lee, S. R. Park, D.-Y. Oh, Y.-I. Park, R. Khosravan, X. Lin, S.-Y. Lee, E.-J. Roh, O. Valota, M. J. Lechuga, Y.-J. Bang
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
Matthew P. Goetz, Heidi A. McKean, Joel M. Reid, Sumithra J. Mandrekar, Angelina D. Tan, Mary A. Kuffel, Stephanie L. Safgren, Renee M. McGovern, Richard M. Goldberg, Axel A. Grothey, Robert McWilliams, Charles Erlichman, Matthew M. Ames
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site
Asuka Tsuya, Takayasu Kurata, Akihiro Tamiya, Isamu Okamoto, Shinya Ueda, Daisuke Sakai, Naotoshi Sugimoto, Koji Matsumoto, Isao Goto, Nobuyuki Yamamoto, Masahiro Fukuoka, Kazuhiko Nakagawa
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
M. Martin-Richard, R. Gallego, C. Pericay, J. Garcia Foncillas, B. Queralt, E. Casado, J. Barriuso, V. Iranzo, I. Juez, L. Visa, E. Saigi, A. Barnadas, X. Garcia-Albeniz, J. Maurel
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
Su Jin Lee, Jongtae Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, In-Gu Do, Sin-Ho Jung, Dong-Seok Yim, Won Ki Kang
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho, Angela M. Davies, Randeep S. Sangha, Derick Lau, Primo Lara Jr., Helen K. Chew, Laurel Beckett, Philip C. Mack, Jonathan W. Riess, David R. Gandara
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas
Jörg Thomas Hartmann, M. Horger, T. Kluba, A. Königsrainer, P. de Zwart, C. Hann von Weyhern, F. Eckert, W. Budach, C. Bokemeyer
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide
Changhoon Yoo, Jeeyun Lee, Sun Young Rha, Kyong Hwa Park, Tae Min Kim, Yu Jung Kim, Hyo Jin Lee, Kyung Hee Lee, Jin-Hee Ahn
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines
Sandra M. Axiak-Bechtel, Senthil R. Kumar, Kristin K. Dank, Nicole A. Clarkson, Kim A. Selting, Jeffrey N. Bryan, Thomas J. Rosol, Jahna Espinosa, Charles J. Decedue
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers
Terry H. Landowski, Betty K. Samulitis, Robert T. Dorr
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)
T. Valentin, C. Fournier, N. Penel, E. Bompas, L. Chaigneau, N. Isambert, C. Chevreau
Erratum to: Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial
Craig Reynolds, Alexander I. Spira, Larry Gluck, Suzanne J. Bradie-Muller, Feng Zhan, Kristi A. Boehm, Lina Asmar